Table 1.
Clinicopathological factors and baseline characteristics.
| Characteristics | BC | Benign breast disease | P-value |
|---|---|---|---|
| Number of patients | 938 | 509 | |
| Age (years) | <0.01 | ||
| Average (SD) | 49.63 (11.07) | 37.49 (11.91) | |
| Median (IQR) | 49 (42,56) | 37 (29,45) | |
| <45 years (%) | 309 (32.94%) | 375 (73.67%) | |
| ≱ 45 to <55 years (%) | 346 (36.89%) | 92 (18.07%) | |
| ≱ 55 years (%) | 283 (30.17%) | 42 (8.25%) | |
| T classification | |||
| T1T2 | 671 (71.54%) | / | |
| T3T4 | 267 (28.46%) | / | |
| N classification | |||
| N0 | 410 (43.71%) | / | |
| N1-3 | 528 (56.29%) | / | |
| M classification | |||
| M0 | 747 (79.64%) | / | |
| M1 | 191 (20.36%) | / | |
| Clinical stage | |||
| I/II | 554 (59.06%) | / | |
| III/IV | 384 (40.94%) | / | |
| Predictive factors | |||
| Progesterone Receptor + (%) | 635 (67.70%) | / | |
| Estrogen Receptor + (%) | 669 (71.32%) | / | |
| HER2+ (%) | 459 (48.93%) | / | |
| Ki_67≧14% (%) | 778 (82.94%) | / | |
| CK5_6 + (%) | 121 (12.90%) | / | |
| EGRF + (%) | 167 (17.80%) | / | |
| Molecular subtypes | / | ||
| Luminal A | 95 (10.13%) | / | / |
| Luminal B(HER2(-)) | 282 (30.06%) | / | / |
| Luminal B(HER2(+)) | 340 (36.25%) | / | / |
| ERBB2(HER2(+)) | 119 (12.69%) | / | / |
| Triple‐negative | 102 (10.87%) | / | / |
| Metastatic and relapse sites | |||
| liver metastasis (%) | 16 (1.71%) | / | / |
| lung metastasis (%) | 3 (0.03%) | / | / |
| distant lymph node (%) | 5 (0.05%) | / | / |
| others (%) | 71 (7.57%) | / | / |
| multiple metastasis (%) | 96 (10.23%) | / | / |
| CEA (median [IQR]) | 1.84 [1.22,3.07] | / | / |
| CA125 (median [IQR]) | 15.30 [10.10,24.98] | / | / |
| CA153 (median [IQR]) | 13.80 [8.10,22.80] | / | / |
| T cell (median [IQR]) | 67.50 [61.50,73.30] | / | / |
| Th (median [IQR]) | 39.40 [33.73,44.50] | / | / |
| Tc (median [IQR]) | 20.77 [16.70,25.58] | / | / |
| Th/Tc ratio(median [IQR]) | 1.90[1.44,2.50] | / | / |
| NK (median [IQR]) | 11.90 [8.40,17.00] | / | / |
| B cell (median [IQR]) | 12.33 [9.02,16.00] | / | / |
| NEUT(median [IQR]) | 3.62 [2.85,4.64] | 3.72 [2.92,4.78] | 0.023 |
| LYMPH (median [IQR]) | 1.75 [1.40,2.12] | 1.84 [1.53,2.11] | 0.118 |
| MONO (median [IQR]) | 0.38 [0.30,0.46] | 0.34 [0.28,0.42] | <0.01 |
| PLT (median [IQR]) | 259.00 [220.00,310.00] | 268.00 [232.00,309.00] | 0.139 |
| NLR (median [IQR]) | 2.04 [1.56,2.86] | 2.04 [1.56,2.65] | 0.239 |
| LMR (median [IQR]) | 4.75 [3.66,6.08] | 5.42 [4.32,6.60] | <0.01 |
| PLR (median [IQR]) | 150.17 [116.71,194.76] | 143.65 [118.75,179.08] | 0.603 |
Wilcoxon test. Bold values indicate significant differences.
EGRF, epidermal growth factor receptor; CEA, carcinoembryonic antigen; CA125, carbohydrate antigen 125; CA153, carbohydrate antigen 153; Th, helper T cell; Tc, killer T cell; NK, natural killer; NEUT, neutrophile; LYMPH, lymphocyte; MONO, monocyte; PLT, platelet; NLR, neutrophil-lymphocyte ratio; LMR, lymphocyte-monocyte ratio; PLR, platelet-lymphocyte ratio.